Immunology & infectious disease Anesthesia & intensive care
Author, co-author :
FRIPPIAT, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
Vercheval, Christelle ; Centre Hospitalier Universitaire de Liège - CHU > Département de pharmacie hospitalière > Service de pharmacie clinique
Benítez-Cano A, Luque S, Sorlí L, Carazo J, Ramos I, Campillo N, Curull V, Sánchez-Font A, Vilaplana C, Horcajada JP, Adalia R, Bermejo S, Samsó E, Hope W, Grau S. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Crit Care. 2020;24:55.
Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med. 2008;36:1500-6.
Heffernan AJ, Sime FB, Lipman J, Dhanani J, Andrews K, Ellwood D, Grimwood K, Roberts JA. Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: a systematic review. Int J Antimicrob Agents. 2019;53:234-45.
Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, Van Bambeke F, Wallemacq P, Descy J, Lambermont B, Layios N, Damas P, Moutschen M. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother. 2015;70:207-16.
Delattre IK, Briquet C, Wallemacq P, Tulkens PM, Van Bambeke F. Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe. Int J Antimicrob Agents. 2020;55:105825.
